Tenax Therapeutics reported a net loss of $50.2 million for the nine months ended September 30, 2026, driven by increased research and development costs for its cardiopulmonary therapies. Despite the loss, the company strengthened its liquidity position to $113.7 million in cash and cash equivalents, primarily through $52.1 million in proceeds from the exercise of warrants and options. Management believes current funds are sufficient to support operations for at least the next 12 months.
Tenax Therapeutics Insider ADAR1 Capital Management LLC Buys $1.46M of Stock
ADAR1 Capital Management LLC bought 922,849 shares of Tenax Therapeutics, Inc. at $1.51 to $1.66 a share (average $1.59) in 3 transactions, worth $1.46M in total between Oct 19, 2026 and Oct 21, 2026. Shares held after the trade: 7,447,000 (+4.7%).
Tenax Therapeutics filed an updated investor presentation detailing strategic changes to its Phase 3 LEVEL-2 clinical trial for TNX-103 in PH-HFpEF. The company is pausing enrollment to amend protocol criteria based on findings from its completed LEVEL trial and has requested a Type C meeting with the FDA to discuss the development path.